AcouSort AB (publ) (ACOU.ST)
SEK 3.75
(-1.32%)
SEK 3.75
(-1.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.37 Million SEK | -53.96% |
| 2022 | 22.54 Million SEK | 537.14% |
| 2021 | 3.53 Million SEK | -1.15% |
| 2020 | 3.57 Million SEK | 69.38% |
| 2019 | 2.11 Million SEK | 13.6% |
| 2018 | 1.86 Million SEK | 74.81% |
| 2017 | 1.06 Million SEK | -48.94% |
| 2016 | 2.08 Million SEK | 1044.6% |
| 2015 | 182.07 Thousand SEK | -66.51% |
| 2014 | 543.6 Thousand SEK | -74.88% |
| 2013 | 2.16 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 8.09 Million SEK | -22.05% |
| 2024 Q2 | 9.74 Million SEK | 20.47% |
| 2023 Q2 | 9.3 Million SEK | -5.73% |
| 2023 FY | 10.37 Million SEK | -53.96% |
| 2023 Q4 | 10.37 Million SEK | 37.58% |
| 2023 Q1 | 9.86 Million SEK | -56.23% |
| 2023 Q3 | 7.54 Million SEK | -18.9% |
| 2022 Q2 | 3.56 Million SEK | 11.21% |
| 2022 FY | 22.54 Million SEK | 537.14% |
| 2022 Q4 | 22.54 Million SEK | 711.45% |
| 2022 Q1 | 3.2 Million SEK | -9.47% |
| 2022 Q3 | 2.77 Million SEK | -22.01% |
| 2021 Q4 | 3.53 Million SEK | -36.21% |
| 2021 Q2 | 5.4 Million SEK | 87.49% |
| 2021 Q1 | 2.88 Million SEK | -19.39% |
| 2021 Q3 | 5.54 Million SEK | 2.53% |
| 2021 FY | 3.53 Million SEK | -1.15% |
| 2020 Q1 | 1.37 Million SEK | -35.02% |
| 2020 Q3 | 1.64 Million SEK | -33.45% |
| 2020 FY | 3.57 Million SEK | 69.38% |
| 2020 Q4 | 3.57 Million SEK | 117.04% |
| 2020 Q2 | 2.47 Million SEK | 80.48% |
| 2019 Q1 | 1.93 Million SEK | 4.09% |
| 2019 Q3 | 1.68 Million SEK | -12.32% |
| 2019 Q4 | 2.11 Million SEK | 25.77% |
| 2019 FY | 2.11 Million SEK | 13.6% |
| 2019 Q2 | 1.91 Million SEK | -1.03% |
| 2018 Q3 | 2.16 Million SEK | 8.54% |
| 2018 FY | 1.86 Million SEK | 74.81% |
| 2018 Q4 | 1.86 Million SEK | -13.89% |
| 2018 Q2 | 1.99 Million SEK | 33.11% |
| 2018 Q1 | 1.49 Million SEK | 40.51% |
| 2017 Q3 | 915 Thousand SEK | -7.67% |
| 2017 Q4 | 1.06 Million SEK | 16.28% |
| 2017 FY | 1.06 Million SEK | -48.94% |
| 2017 Q2 | 991 Thousand SEK | 34.65% |
| 2017 Q1 | 736 Thousand SEK | -64.68% |
| 2016 FY | 2.08 Million SEK | 1044.6% |
| 2016 Q4 | 2.08 Million SEK | 105.93% |
| 2016 Q3 | 1.01 Million SEK | 0.0% |
| 2015 Q4 | 182.07 Thousand SEK | 0.0% |
| 2015 FY | 182.07 Thousand SEK | -66.51% |
| 2014 FY | 543.6 Thousand SEK | -74.88% |
| 2013 FY | 2.16 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -11.221% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -134.478% |
| BioArctic AB (publ) | 139.5 Million SEK | 92.561% |
| Camurus AB (publ) | 414.81 Million SEK | 97.498% |
| Kancera AB (publ) | 17.97 Million SEK | 42.274% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 10.295% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 74.6% |
| Xintela AB (publ) | 14.01 Million SEK | 25.951% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -339.932% |
| Active Biotech AB (publ) | 13.4 Million SEK | 22.552% |
| Amniotics AB (publ) | 10.54 Million SEK | 1.602% |
| Cantargia AB (publ) | 54.97 Million SEK | 81.121% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -170.401% |
| CombiGene AB (publ) | 4.15 Million SEK | -149.711% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 85.407% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 24.642% |
| Genovis AB (publ.) | 98.04 Million SEK | 89.415% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 43.885% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 45.846% |
| Saniona AB (publ) | 86.08 Million SEK | 87.944% |
| OncoZenge AB (publ) | 1.69 Million SEK | -510.83% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 90.264% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.337% |
| Mendus AB (publ) | 51.22 Million SEK | 79.74% |
| Intervacc AB (publ) | 21.68 Million SEK | 52.131% |
| LIDDS AB (publ) | 3.75 Million SEK | -176.305% |
| Lipum AB (publ) | 7.53 Million SEK | -37.676% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -101.202% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 91.629% |
| NextCell Pharma AB | 13.68 Million SEK | 24.188% |
| Simris Alg AB (publ) | 148.93 Million SEK | 93.032% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 11.056% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -99.771% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.848% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 85.556% |
| Ziccum AB (publ) | 6.38 Million SEK | -62.461% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 70.008% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 61.143% |
| Corline Biomedical AB | 6.78 Million SEK | -52.865% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 83.086% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 35.608% |
| Aptahem AB (publ) | 8.99 Million SEK | -15.339% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 77.527% |
| Fluicell AB (publ) | 8.91 Million SEK | -16.411% |
| Biovica International AB (publ) | 34.76 Million SEK | 70.15% |
| Abliva AB (publ) | 16.78 Million SEK | 38.156% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 95.164% |
| 2cureX AB (publ) | 2.93 Million SEK | -253.595% |
| I-Tech AB | 16.2 Million SEK | 35.958% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.125% |
| Cyxone AB (publ) | 4.69 Million SEK | -121.091% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 22.134% |
| Biosergen AB | 5.08 Million SEK | -104.09% |
| Nanologica AB (publ) | 79.32 Million SEK | 86.917% |
| SynAct Pharma AB | 51.83 Million SEK | 79.978% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -30.557% |
| BioInvent International AB (publ) | 90.45 Million SEK | 88.527% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 94.285% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -478.484% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 18.566% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -42.948% |